BIA response to DHSC consultation on the future strategy for batch testing of medicines in Great Britain

The BIA has responded to the Department of Health and Social Care consultation on the future strategy for batch testing of medicines in Great Britain. The consolidated BIA response was developed with input from our Regulatory Affairs Advisory Committee. It is important that the consultation outcome supports the ambitions of the Life Sciences Vision and ensures that the UK retains and grows its reputation as a world-leading base for innovation and investment in R&D, while protecting patient safety and access to medicines, and maintaining globally harmonised standards.